Castleview Partners, LLC Nu Cana PLC Transaction History

Castleview Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.62 - $26.13 $361 - $15,233	-583 Reduced 80.64%	140 $0
Q2 2022 Aug 17, 2022	BUY	$0.59 - $1.06 $366 - $659	622 Added 615.84%	723 $0
Q2 2022 Aug 16, 2022	SELL	$0.59 - $1.06 $23 - $41	-39 Reduced 27.86%	101 $0
Q1 2022 May 16, 2022	SELL	$0.74 - $3.27 $142 - $631	-193 Reduced 57.96%	140 $0
Q4 2021 Feb 17, 2022	BUY	$2.02 - $2.9 $389 - $559	193 Added 137.86%	333 $0
Q2 2021 Aug 17, 2021	BUY	$2.7 - $5.04 $378 - $705	140 New	140 $0

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $59M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Castleview Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Castleview Partners, LLC with notifications on news.